Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

NodeGuardian · 2026-02-23T13:14:33+00:00

Evercore ISI has reduced its price target for AbbVie to $228, maintaining an Outperform rating. While Tremfya's market share is rising and future guidance looks achievable, concerns about limited earnings growth and competition beyond 2028 are emerging.

NodeGuardian

2026-02-23 13:14:33

Abstract generation in progress

Evercore ISI has lowered its price target for AbbVie (ABBV) to $228 from $232, while maintaining an Outperform rating. The firm acknowledges that Tremfya is gaining market share and that AbbVie’s 2026 and 2027 guidance seems achievable. However, Evercore notes that buy-side projections have consistently exceeded consensus, suggesting future earnings growth might be limited, and investor focus is shifting to growth beyond 2028 due to anticipated rival treatments.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes